StageZero Life Sciences (TSX:SZLS) Interest Expense : C$-0.31 Mil (TTM As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. StageZero Life Sciences's interest expense for the three months ended in Sep. 2023 was C$ -0.04 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was C$-0.31 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. StageZero Life Sciences's Operating Income for the three months ended in Sep. 2023 was C$ -1.03 Mil. StageZero Life Sciences's Interest Expense for the three months ended in Sep. 2023 was C$ -0.04 Mil. StageZero Life Sciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

StageZero Life Sciences Interest Expense Historical Data

The historical data trend for StageZero Life Sciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Interest Expense Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-0.78

-0.87

-0.41

-0.26

-0.30

StageZero Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial															-0.09	-0.08	-0.06	-0.13	-0.04

StageZero Life Sciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.31 Mil.

StageZero Life Sciences (TSX:SZLS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

StageZero Life Sciences's Interest Expense for the three months ended in Sep. 2023 was C$-0.04 Mil. Its Operating Income for the three months ended in Sep. 2023 was C$-1.03 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was C$1.00 Mil.

StageZero Life Sciences's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

StageZero Life Sciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

StageZero Life Sciences (TSX:SZLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SZLSF:USA 61N1:Germany

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

StageZero Life Sciences (TSX:SZLS) Headlines

No Headlines